Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 6:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2545–2568 of 3,702 matching trials from the live ClinicalTrials.gov search.
Completed Phase 2 Interventional Results available

A Study in Non-Small Cell Lung Cancer

NCT01232452
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
Pemetrexed, Cisplatin, Cixutumumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
5
States / cities
Chicago, Illinois • Hackensack, New Jersey • Portland, Oregon + 2 more
Conditions
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Colon Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Non-small Cell Lung Cancer, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage III Adenoid Cystic Carcinoma of the Oral Cavity, Stage III Basal Cell Carcinoma of the Lip, Stage III Colon Cancer, Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage III Lymphoepithelioma of the Nasopharynx, Stage III Lymphoepithelioma of the Oropharynx, Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage III Mucoepidermoid Carcinoma of the Oral Cavity, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IIIB Non-small Cell Lung Cancer, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Basal Cell Carcinoma of the Lip, Stage IV Colon Cancer, Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Lymphoepithelioma of the Oropharynx, Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Non-small Cell Lung Cancer, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Renal Cell Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions
erlotinib hydrochloride, cetuximab, bevacizumab, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma), NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions
daraxonrasib, docetaxel
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
53
States / cities
Birmingham, Alabama • Loma Linda, California • Long Beach, California + 43 more
Conditions
Non-Small-Cell Lung Cancer
Interventions
Pioglitazone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Bethesda, Maryland • New York, New York
Conditions
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
Interventions
Pembrolizumab
Biological
Lead sponsor
Joel Neal
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Tumor Pathway Activations Inhibited by Dovitinib
Interventions
Dovitinib (TKI258)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
49
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Pismo Beach, California + 43 more
Conditions
Non-small Cell Lung Cancer
Interventions
PET-based, dose-painted, accelerated chemoradiotherapy, Standard chemoradiotherapy
Combination Product
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Non-Small Cell Lung Carcinoma
Interventions
Albumin-bound paclitaxel, Paclitaxel, Carboplatin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
1,052 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
31
States / cities
Huntsville, Alabama • Hot Springs, Arkansas • Little Rock, Arkansas + 27 more
Conditions
Lung Neoplasms, Carcinoma Non-small-cell Lung
Interventions
Multifocal Tissue Banking
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma
Interventions
RP1, nivolumab
Biological
Lead sponsor
Replimune, Inc.
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
26
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 21 more
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Not listed
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years and older
Enrollment
7,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
17
States / cities
Daphne, Alabama • Prescott Valley, Arizona • Denver, Colorado + 14 more
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Paclitaxel and carboplatin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
56
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Springdale, Arkansas + 47 more
Conditions
Non-Small Cell Lung Cancer
Interventions
Atezolizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
667 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
37
States / cities
Gilbert, Arizona • Scottsdale, Arizona • Duarte, California + 31 more
Conditions
Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Unresectable Non-Small Cell Lung Cancer, Stage IIIb-d Malignant Melanoma
Interventions
Plasma sample collection
Other
Lead sponsor
OncoHost Ltd.
Industry
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
12
States / cities
Birmingham, Alabama • Jacksonville, Florida • Miami, Florida + 8 more
Conditions
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Interventions
ABP 234, Pembrolizumab (US), Pembrolizumab (EU)
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
15
States / cities
Beverly Hills, California • Cerritos, California • Los Alamitos, California + 12 more
Conditions
Solid Tumor, Adult, Triple Negative Breast Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Osteosarcoma, Epithelial Ovarian Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Malignant Melanoma
Interventions
CRX100 suspension for infusion, Fludarabine, Cyclophosphamide
Biological · Combination Product
Lead sponsor
BioEclipse Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Scottsdale, Arizona • La Jolla, California • Stanford, California
Conditions
Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer, Colorectal Cancer, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma
Interventions
ALE.P03
Drug
Lead sponsor
Alentis Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 6 more
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Savolitinib, Osimertinib, Pemetrexed, Cisplatin, Carboplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
5
States / cities
Orlando, Florida • Honolulu, Hawaii • New Brunswick, New Jersey + 2 more
Conditions
Metastatic Malignant Neoplasm in the Lung, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Adult Soft Tissue Sarcoma, Stage IV Non-Small Cell Lung Cancer
Interventions
Cisplatin, Pharmacological Study
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent, Non-squamous EGFR Wt NSCLC, Platinum Resistant Ovarian Cancer, PROC
Interventions
HWK-007
Drug
Lead sponsor
Whitehawk Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
12
States / cities
Little Rock, Arkansas • Los Angeles, California • Peoria, Illinois + 9 more
Conditions
Non-small Cell Lung Cancer, Extensive Stage Unresectable
Interventions
Docetaxel, Irinotecan, Carboplatin
Drug
Lead sponsor
Kentuckiana Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Louisville, Kentucky
Completed No phase listed Observational Accepts healthy volunteers

Family Quality of Life Among Families With a Member Who is a Cancer Patient

NCT00544336
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer, Solid Tumor
Interventions
questionnaire administration, survey administration, quality-of-life assessment
Other · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
21 Years and older
Enrollment
366 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
3
States / cities
Nashville, Tennessee
Conditions
Non-Small Cell Lung Cancer
Interventions
Nivolumab, Bevacizumab, Pemetrexed, Best Supportive Care, nab-Paclitaxel, Paclitaxel, Docetaxel, Gemcitabine, Erlotinib, Crizotinib, Carboplatin
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
133
States / cities
Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 117 more
Conditions
Neoplasms, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Bronchial Neoplasms, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms, Digestive System Neoplasms, Endocrine Gland Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Breast Neoplasms, Breast Diseases, Renal Neoplasm, Solid Tumors
Interventions
Entinostat, Placebo
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Antonio, Texas